The Center for Genetic Engineering and Biotechnology (, CIGB) is a research institute in Havana, Cuba.
Founding
In 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World. Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy. Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB.
Activity
In 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers.[1] Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers.[1]
As of 2017, CIGB had 1,600 employees and sold 21 products internationally.
As of 2020, CIGB had two joint ventures with China.[2]